Stay updated with breaking news from Jon Chen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- IsoPlexis, the leader in functional single-cell proteomics, today announced the acquisition of an extensive intellectual property portfolio of...
Published: May 18, 2021 IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe. BRANFORD, Conn., May 18, 2021 /PRNewswire/ -- IsoPlexis, the leader in single-cell proteomics, today announced an exclusive agreement with Bucher Biotec AG, a Swiss distributor company representing some of the most advanced US, European, and Asian manufacturers of highly innovative life science research instrumentation, associated reagents, and consumables. This agreement follows Iso...
Share this article Share this article BRANFORD, Conn., May 13, 2021 /PRNewswire/ -- IsoPlexis, the leader in single-cell proteomics, today announced that Jason Ou has joined the company as General Manager for the Asia-Pacific (APAC) region. In this role, Mr. Ou will continue to advance IsoPlexis' growth and expand the company's customer base in the APAC region. "We are pleased to have Jason join our leadership team at IsoPlexis," said Peter Siesel, Chief Commercial Officer of IsoPlexis. "Jason has an extensive track record of leadership, solution-oriented thinking, and customer satisfact...
IsoPlexis Appoints Siddhartha Kadia to its Board of Directors News provided by Share this article Share this article BRANFORD, Conn., May 11, 2021 /PRNewswire/ -- IsoPlexis, the leader in functional single-cell proteomics, today announced the appointment of Siddhartha Kadia to its Board of Directors. Dr. Kadia joins IsoPlexis' Board of Directors with over 20 years of experience in evolving a combination of technology, life science and healthcare industries. Dr. Siddhartha Kadia previously served as the President of the Life Sciences division at Life Technologies, where he managed $2B P&L whi...
IsoPlexis Announces $135 Million Financing Led by Perceptive Advisors Posted Jan 08, 2021 BRANFORD, Conn., Jan. 8, 2021 /BiopharmaDive/ -- IsoPlexis, the leader in single-cell functional proteomics, announced a $135 million Series D financing comprised of $85 million in equity securities and a $50 million credit facility. The round was led by Perceptive Advisors with participation from other new investors, Ally Bridge Group and funds and accounts managed by BlackRock, as well as other existing investors. IsoPlexis will use the proceeds from this financing to expand its g...